Reportstack has announced a new market research publication on Investigation Report on China Enoxaparin Sodium Market, 2009-2018. Thrombosis is the formation of a blood clot inside a blood vessel, obstructing the flow of blood through the circulatory system. It can result in anoxia, the complete deprivation of oxygen and infarction, and even tissue death. Twelve million people worldwide are killed every year by cardiovascular and cerebrovascular diseases such as cerebral thrombosis, cerebral infarction, myocardial infarction, coronary heart disease and arteriosclerosis. It equals to nearly one-fourth of global death toll. Incidence of cardiovascular diseases keeps rising in China. The number of cardiovascular diseases patients in China now is estimated to be 290 million with 2 patients among 10 adults. It is estimated that about 3.5 million people die of cardiovascular diseases every year in China. This number has topped all diseases and takes up 40% of total death toll.
Heparin drugs are widely used in hemodialysis and various surgical operations. Because low-molecular-weight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Low-molecular-weight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993 with the trade name "Lovenox". The active ingredient of the medication is a natural derivative of certain type of sugar molecule. Enoxaparin sodium injection produced by Sanofi was approved to the U.S. market in October 2004 by the FDA. It entered Chinese market early 2005.
Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. It can prevent thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have gone on the market in succession since 2010, leading to a dramatic sales drop of similar products produced by Sanofi. The downstream market is thus reorganized. Global sales revenue of Lovenox in 2012 is approximately USD 2.5 billion, which decreased 10.3% YOY.
Four manufacturers in China have received production approval of enoxaparin sodium injection by early 2014. According to investigation, products of Sanofi and its related enterprises occupy most market share in Chinese sample hospitals, followed by Hangzhou Jiuyuan Gene Engineering Co., Ltd.
The CAGR of sales value of enoxaparin sodium injection in Chinese sample hospitals exceeded 17% from 2005 to 2012. On the one hand, incidence of vascular embolism keeps rising due to population aging in China. On the other hand, operations such as cardiovascular and cerebrovascular intervention develop rapidly. Followed up by the development of anticoagulation, antiplatelet and hypolipidemic treatment after stent surgery, antithrombotic drug market has been greatly expanded in China.
It is estimated that enoxaparin sodium market in China will rise significantly in the next few years.
Through this report, the readers can acquire the following information:
-Incidence of Thrombosis in China
-Market Share of Major Enoxaparin Sodium Manufacturers in China Sample Hospitals
-Sales price of Enoxaparin Sodium in China Hospital Market
-Production Status of Enoxaparin Sodium Generic Drug in China
-Major Enoxaparin Sodium Manufacturers in China
- Prospect of China Enoxaparin Sodium Market
The following enterprises and people are recommended to purchase this report:
-Anti-clotting Drugs Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Anti-clotting Drug Market
Heparin drugs are widely used in hemodialysis and various surgical operations. Because low-molecular-weight heparin preparation is more widely used in clinical practice than unfractionated heparin preparation, the later is gradually being replaced by the former. Low-molecular-weight heparin preparation took up over 85% of the global heparin market from 2005 to 2010. Enoxaparin sodium is an important variety of low-molecular-weight heparin preparations, which is originally developed by Aventis (later merged with Sanofi). It was approved to the market in 1993 with the trade name "Lovenox". The active ingredient of the medication is a natural derivative of certain type of sugar molecule. Enoxaparin sodium injection produced by Sanofi was approved to the U.S. market in October 2004 by the FDA. It entered Chinese market early 2005.
Enoxaparin sodium can not only prevent DVT (deep vein thrombosis) and pulmonary embolism but also treat venous thrombosis. It can prevent thrombus in extracorporeal circulation during hemodialysis, and treat unstable angina and non-Q-wave myocardial infarction. Enoxaparin sodium generic drugs produced by Sandoz and Amphastar Pharm have gone on the market in succession since 2010, leading to a dramatic sales drop of similar products produced by Sanofi. The downstream market is thus reorganized. Global sales revenue of Lovenox in 2012 is approximately USD 2.5 billion, which decreased 10.3% YOY.
Four manufacturers in China have received production approval of enoxaparin sodium injection by early 2014. According to investigation, products of Sanofi and its related enterprises occupy most market share in Chinese sample hospitals, followed by Hangzhou Jiuyuan Gene Engineering Co., Ltd.
The CAGR of sales value of enoxaparin sodium injection in Chinese sample hospitals exceeded 17% from 2005 to 2012. On the one hand, incidence of vascular embolism keeps rising due to population aging in China. On the other hand, operations such as cardiovascular and cerebrovascular intervention develop rapidly. Followed up by the development of anticoagulation, antiplatelet and hypolipidemic treatment after stent surgery, antithrombotic drug market has been greatly expanded in China.
It is estimated that enoxaparin sodium market in China will rise significantly in the next few years.
Through this report, the readers can acquire the following information:
-Incidence of Thrombosis in China
-Market Share of Major Enoxaparin Sodium Manufacturers in China Sample Hospitals
-Sales price of Enoxaparin Sodium in China Hospital Market
-Production Status of Enoxaparin Sodium Generic Drug in China
-Major Enoxaparin Sodium Manufacturers in China
- Prospect of China Enoxaparin Sodium Market
The following enterprises and people are recommended to purchase this report:
-Anti-clotting Drugs Manufacturers
-Medical Institutions
-Investors /Research Agencies Focusing on Anti-clotting Drug Market
To view the table of contents and know more details please visit Investigation Report on China Enoxaparin Sodium Market, 2009-2018.
No comments:
Post a Comment